Abstract
AIDS:
Development of a safe and effective AIDS vaccine remains a critical issue, particularly in developing nations where HIV infections will account for 90 percent of all new infections by 2000. The AIDS Vaccine Evaluation Group (AVEG) is conducting phase I and II studies of several candidate HIV-1 vaccines. Technical and ethical issues, including significant problems that need to be addressed in vaccine trials, are discussed. The safety of the current candidate vaccines, their immunogenicity, and the continued spread of HIV-1 in spite of educational efforts indicate that clinical trials are warranted. An extensive bibliography of articles related to vaccine development is included.
MeSH terms
-
AIDS Vaccines / genetics
-
AIDS Vaccines / immunology*
-
AIDS Vaccines / therapeutic use
-
Animals
-
Avipoxvirus / immunology*
-
Clinical Trials as Topic*
-
Genetic Vectors
-
HIV Envelope Protein gp120 / therapeutic use
-
HIV Envelope Protein gp160 / therapeutic use
-
HIV Infections / immunology
-
HIV Infections / prevention & control*
-
HIV Infections / transmission
-
HIV-1*
-
Humans
-
Immunotherapy / methods
-
United States
-
Vaccines, Synthetic / immunology
-
Vaccines, Synthetic / therapeutic use
-
Viral Vaccines / genetics
-
Viral Vaccines / immunology*
-
Viral Vaccines / therapeutic use
Substances
-
AIDS Vaccines
-
HIV Envelope Protein gp120
-
HIV Envelope Protein gp160
-
Vaccines, Synthetic
-
Viral Vaccines